| 12383539 |
Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
Spyridon Papapetropoulos, Michelle Higgin, Muralikrishna Duvvuri, Bruce Rehlaender, Evan Newbold |
2025-08-12 |
| 12077502 |
Formulations of T-type calcium channel modulators and methods of use thereof |
Kiran Reddy, Gabriel Maurice Belfort, Sapna Makhija Garad, Mahesh Padval, Randall Wagner +1 more |
2024-09-03 |
| 11602530 |
CRM1 inhibitors for treating epilepsy |
Sharon Tamir, Marc Roger de Ryck, Rafal Kaminski, Karine Leclercq, Benoit Kenda |
2023-03-14 |
| 11427540 |
Formulations of T-type calcium channel modulators and methods of use thereof |
Kiran Reddy, Gabriel Maurice Belfort, Sapna Makhija Garad, Mahesh Padval, Randall Wagner |
2022-08-30 |
| 11311522 |
Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
Spyridon Papapetropoulos, Michelle Higgin, Muralikrishna Duvvuri, Bruce Rehlaender, Evan Newbold |
2022-04-26 |
| 11236078 |
Heterocyclic inhibitors of the sodium channel |
Glenn SHORT, Donna L. Romero |
2022-02-01 |
| 7795310 |
Methods and reagents for the treatment of metabolic disorders |
Grant Zimmermann, Alyce Finelli, Daniel Grau, Curtis Keith, M. Nichols |
2010-09-14 |